Alumis Inc.

NASDAQ: ALMS · Healthcare · Biotechnology

PublicHQ South San Francisco, CA · San MateoCIK 0001847367Reports USD

#525 of 1,394 Healthcare companies by revenue

EA Score

35D

FH 41DQ 21GM —SS 57

v0.1 · 55/100 weight · provisional

↑ Altman-Z, market scale · ↓ disclosure history, Piotroski F

Methodology →

Revenue TTM

$8.4M

Rev growth YoY (TTM)

-51.7%

Net income (FY)

-$243.3M

Employees

223

Market cap

$3.3B

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$24.1M$24.1M2025

Net income-$243.3M-$243.3M2025

Operating income-$453.8M-$453.8M2025

Total assets$411.9M$411.9M2025

Liabilities$110.6M$110.6M2025

Equity$301.3M$301.3M2025

Revenue by segment

Filed disclosures · FY2025

By product

License72%

Collaboration Revenue28%

By geography

Not disclosed.

The read

Alumis Inc. booked $24.1M in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -1011.7% net margin.

Peers · Healthcare

Relay Therapeutics, Inc.58C Ultragenyx Pharmaceutical Inc.58C Integer Holdings Corporation84B+Arcutis Biotherapeutics, Inc.66B

Neighbors

San Mateo →

Meta Platforms, Inc.$201.0B87A Gilead Sciences, Inc.$29.4B87A Robinhood Markets, Inc.$4.5B67B Equinix, Inc.$9.2B73B Electronic Arts Inc.$7.5B82B+Revolution Medicines, Inc.$052D

Key facts

CEOMartin Babler

SectorHealthcare

IndustryBiotechnology

HeadquartersSouth San Francisco, CA

ExchangeNASDAQ: ALMS

Employees223

IPO date2024-06-28

Latest filings

8-K2026-07-02 8-K2026-06-29 DEF 14A2026-05-18 10-Q2026-05-14 8-K2026-05-14 8-K2026-03-30 8-K2026-03-19 10-K2026-03-19

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.